AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: net buying of $2K to $30K in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- +$2K to +$30K netNet buying
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 4 added, 3 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $431.16
- 52-wk high
- $553.56
- High
- $443.15
- 52-wk low
- $353.34
- Low
- $431.16
- Prev close
- $435.61
- Mkt cap
- $95.75B
- P/E
- 14.5x
- Volume
- 1.05M
- Fwd P/E
- 13.8x
- Beta
- 1.11
- Div yield
- 0.69%
- P/S
- 1.2x
- P/B
- 291.3x
- Profit margin
- +8.8%
- Op margin
- +15.2%
- ROE
- +136.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about HCA filings
Are insiders buying or selling HCA Healthcare, Inc. (HCA) stock?
Neither. HCA Healthcare, Inc. (HCA) insiders filed no open-market purchases or sales in the 90 days to Oct 1, 2026, according to SEC Form 4 filings.
Which members of Congress have traded HCA recently?
Rep. Jared Moskowitz (D) bought $1K to $15K on Jun 17, 2026, disclosed 39 days later. Rep. Jared Moskowitz (D) bought $1K to $15K on Jun 17, 2026, disclosed 39 days later. In total, 1 member disclosed 2 HCA trades with trade dates in the last 180 days, filed a median 39 days after trading.
How current is this HCA smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position.
What funds are doing
Buys/Adds (1)
- DS
D.E. Shaw
$30.7M
added
Sells/Trims (2)
- VG
Viking Global
$466.5M
sold
- QR
Qube Research
$52.3M
trimmed
What Congress is doing
How top traders are positioned
No tracked top-trader positions in HCA right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings landed in line with what analysts expected.
Earnings per share
$7.57 expected
Revenue
No comparable estimate
FY2026 guidance
$77.00B to $79.50B
No comparable estimate
Reports Oct 23, 2026, in 22 days
Estimates as of Sep 30, 2026
EPS expected
$5.83 to $7.35
Revenue expected
21 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $19.16B | $19.51B | $19.11B | $20.23B |
| Cost of what it sold | $11.15B | $11.34B | $16.25B | $17.16B |
| Gross profit | $8.02B | $8.18B | $2.86B | $3.07B |
| What it spent | ||||
| Sales and admin | $7.86B | $8.36B | — | — |
| Other operating costs | -$2.81B | -$3.36B | $16.25B | $17.16B |
| Total operating expenses | $5.05B | $5.00B | $16.25B | $17.16B |
| What was left | ||||
| Operating profit | $2.96B | $3.18B | $2.86B | $3.07B |
| Interest on debt | $561.0M | $572.0M | $584.0M | $599.0M |
| Profit before tax | $2.42B | $2.67B | $2.29B | $2.49B |
| Tax | $515.0M | $509.0M | $430.0M | $564.0M |
| Net profit | $1.64B | $1.88B | $1.62B | $1.70B |
| EBITDA | $3.87B | $4.16B | $3.80B | $4.01B |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
75 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Medical Properties Trust Forms Warning Pattern
Leans bearishSep 27Cryoport shares jump 82% YTD on strong cell and gene therapy pipeline and profitability rebound
Leans bearishSep 26Hope Fund Week 2026: Colleagues caring for each other when they need it most
BullishSep 25Expert Voices: HCA Healthcare physician shares how pulsed field ablation is transforming atrial fibrillation care
BullishSep 25Can Community Health Sustain Growth as Elective Demand Softens?
Leans bullishSep 25Can Community Health Sustain Growth as Elective Demand Softens?
NeutralSep 25Solid Biosciences is a speculative buy with promising gene therapy and cash runway into 2028
NeutralSep 25This HCA Healthcare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
BullishSep 25
Macro
21 macro signals shaping HCA right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results